V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20063182 | 20086862 | 1.69 | 76.8 | 03 | 2018-11-04 | 2018-11-12 | PLATO Trials | N | null | PLATO TRIAL | 100545434 |
| 20063238 | 20086863 | 0 | 0 | Palliative (P) | 2018-02-19 | 2018-03-12 | Bevacizumab + Oxaliplatin +MdG | 02 | N | PHITT D SIOPEL-4 (A1, A2, A3) | 100180537 |
| 20063295 | 20086865 | 0 | 76.8 | null | 2019-11-20 | 2019-12-14 | R GCVP | null | N | GEMCITABINE + PACLITAXEL | 100751730 |
| 20063333 | 20086866 | 1.77 | 79 | Palliative (P) | 2019-06-05 | 2019-06-05 | POMALIDOMIDE | Y | N | RALTITREXED | 100792190 |
| 20063478 | 20086867 | 1.63 | 75.4 | Palliative (P) | 2016-03-19 | 2016-03-23 | AML 19 TRIAL | 02 | null | INTERAACT TRIAL | 100756910 |
| 20063509 | 20086868 | 1.68 | 85.9 | Adjuvant (A) | 2021-05-12 | 2021-05-21 | FCiSt | 02 | N | HYDROXYCARBAMIDE | 100981791 |
| 20063535 | 20086870 | 1.6 | 67.7 | null | 2018-08-11 | 2018-08-11 | IBRUTINIB | 2 | Y | CARBOPLATIN + DOCETAXEL | 101050887 |
| 20063629 | 20086871 | 1.69 | 66.3 | Palliative (P) | 2020-01-16 | 2020-02-05 | PACLITAXEL | 2 | N | IRINOTECAN | 101427593 |
| 20063661 | 20086872 | 1.58 | 71.1 | null | 2020-05-10 | 2020-05-11 | NIVOLUMAB | 02 | N | CISPLATIN + RT | 100434713 |
| 20063697 | 20086873 | null | 88.1 | Palliative (P) | 2019-07-25 | 2019-08-22 | BENDAMUSTINE + RITUXIMAB | 01 | N | PACLITAXEL | 101825478 |
| 20063709 | 20086874 | 1.69 | 52.7 | Adjuvant (A) | 2016-09-06 | 2016-09-06 | null | 01 | null | ESPAC TRIAL | 100147996 |
| 20063853 | 20086875 | 1.9 | 97.9 | null | 2015-10-17 | 2015-10-17 | Fulvestrant + Palbociclib | 02 | N | ARISTOTLE TRIAL | 101153977 |
| 20063925 | 20086876 | 1.84 | 81 | 03 | 2017-03-27 | 2017-04-01 | Doxorubicin + Olaratumab | 02 | N | CAP + RT | 101772865 |
| 20064134 | 20086878 | null | 86.4 | Palliative (P) | 2019-03-27 | 2019-03-27 | Raltitrexed | N | N | CISPLATIN + FLUOROURACIL + RT | 100233493 |
| 20064153 | 20086879 | 1.83 | 91.5 | Palliative (P) | 2018-07-08 | 2018-07-14 | EEF or EOF | 02 | N | ACTICCA-1 TRIAL | 100378089 |
| 20064203 | 20086880 | 0 | 0 | null | 2018-11-08 | 2018-11-15 | ESPAC-4 TRIAL | 02 | N | HYDROXYCARBAMIDE | 100429173 |
| 20064306 | 20086881 | 1.65 | 71.5 | 03 | 2017-11-02 | 2017-11-04 | ESPAC-4 TRIAL | 01 | null | RALTITREXED | 100222227 |
| 20064341 | 20086882 | null | 50.2 | Palliative (P) | 2017-02-11 | 2017-02-11 | PLATO Trials | 2 | N | PLATO TRIAL | 101664633 |
| 20064385 | 20086883 | 1.63 | 69.1 | 03 | 2017-05-27 | 2017-05-27 | Hydroxycarbamide | 02 | N | AML19 TRIAL | 101207198 |
| 20064390 | 20086884 | 1.75 | 68.8 | Adjuvant (A) | 2018-10-22 | 2018-10-22 | Bortezomib +/- Dexamethasone | 02 | N | REGORAFENIB | 101325809 |
| 20064427 | 20086885 | 1.63 | 49 | 03 | 2017-05-10 | 2017-05-10 | EC | 02 | N | PEMBROLIZUMAB | 101817598 |
| 20064498 | 20086886 | 1.6 | 89 | Palliative (P) | 2021-01-20 | 2021-02-02 | EVEROLIMUS | 02 | N | OXALIPLATIN | 101062441 |
| 20064608 | 20086887 | 1.81 | 106 | Palliative (P) | 2019-09-12 | 2019-09-22 | Bortezomib + MELPHALAN | Y | Y | CAPECITABINE + STREPTOZOCIN | 101795504 |
| 20064628 | 20086888 | 1.68 | 51.95 | Adjuvant (A) | 2017-09-09 | 2017-10-07 | ACELARATE Trial | 02 | null | CISPLATIN + FLUOROURACIL + TRASTUZUMAB | 100480368 |
| 20064678 | 20086889 | 0 | 93.7 | Palliative (P) | 2016-09-23 | 2016-10-06 | Paclitaxel 7 day | N | N | PEMBROLIZUMAB | 101019356 |
| 20064704 | 20086890 | 1.77 | 100.6 | Palliative (P) | 2021-02-14 | 2021-02-27 | Docetaxel 75mg/m2 (21 day) | 02 | null | PACLITAXEL | 101819120 |
| 20064804 | 20086891 | 1.81 | 55 | 03 | 2018-07-22 | 2018-07-22 | Docetaxel 75mg/m2 (21 day) | 02 | N | ACELARATE TRIAL | 101609646 |
| 20064967 | 20086892 | 1.59 | 73.5 | Palliative (P) | 2019-01-03 | 2019-02-06 | ACTICCA-1 Trial | N | N | CARBOPLATIN + FLUOROURACIL + STREPTOZOCIN | 101201884 |
| 20065092 | 20086893 | 1.63 | 62.4 | Palliative (P) | 2016-01-11 | 2016-01-26 | EVEROLIMUS | 02 | null | NIVOLUMAB | 101785142 |
| 20065104 | 20086894 | 1.55 | 63 | 03 | 2020-10-22 | 2020-10-22 | PEMBROLIZUMAB | 02 | Y | ACTICCA-1 TRIAL | 101677592 |
| 20065194 | 20086895 | 0 | 58.65 | Palliative (P) | 2019-09-24 | 2019-10-16 | PEMBROLIZUMAB | 02 | N | GEMCITABINE + PACLITAXEL | 100836554 |
| 20065226 | 20086896 | 1.59 | 64.1 | 03 | 2016-09-04 | 2016-09-27 | Capital Trial | 02 | Y | ALECTINIB | 100240347 |
| 20065230 | 20086897 | 1.81 | 79.3 | Curative (C) | 2019-08-15 | 2019-08-17 | CEMIPLIMAB | 02 | N | CYTARABINE | 101587740 |
| 20065236 | 20086898 | 1.73 | 90.4 | 03 | 2018-04-03 | 2018-05-01 | EVEROLIMUS | 02 | null | ECARBOX | 100788673 |
| 20065289 | 20086899 | 1.5 | 72.4 | 03 | 2017-05-22 | 2017-05-22 | BALLAD Trial | 01 | N | ECARBOX | 100129810 |
| 20065308 | 20086900 | 1.73 | 85.3 | null | 2019-12-17 | 2019-12-25 | CAP + RT | 02 | N | EVEROLIMUS | 100424129 |
| 20065426 | 20086901 | 1.62 | 75.2 | 03 | null | 2018-03-01 | EC | 02 | N | CAPECITABINE + STREPTOZOCIN | 100459119 |
| 20065474 | 20086902 | 1.65 | 61 | Palliative (P) | null | 2018-12-15 | STREPTOZOCIN | null | N | CARBOPLATIN + VINORELBINE | 100647715 |
| 20065498 | 20086903 | 1.8 | 73.3 | 03 | 2019-07-16 | 2019-08-12 | CARBOPLATIN + FLUOROURACIL | null | N | CISPLATIN + FLUOROURACIL + RT | 101105340 |
| 20065554 | 20086904 | 1.7 | 84.9 | Palliative (P) | 2017-04-05 | 2017-05-30 | OXALIPLATIN + MDG + PANITUMUMAB | null | N | CISPLATIN + FLUOROURACIL + RT | 100051064 |
| 20065581 | 20086905 | 1.83 | 70.7 | Curative (C) | 2018-12-17 | 2018-12-17 | ACELARATE Trial | 02 | N | PLATO TRIAL | 101282372 |
| 20065621 | 20086907 | 1.78 | 50 | 03 | 2018-03-14 | 2018-03-17 | CISPLATIN + TEYSUNO | 02 | N | ECARBOX | 100969200 |
| 20065637 | 20086908 | 1.77 | 76.1 | 03 | 2019-06-20 | 2019-06-28 | Cetuximab + Radiotherapy Load | null | N | ECARBOX | 100222094 |
| 20065673 | 20086909 | 1.91 | 84.45 | Palliative (P) | 2019-10-12 | 2019-10-26 | ARISTOTLE TRIAL | 01 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + RITUXIMAB + VINCRISTINE | 100891152 |
| 20065730 | 20086910 | 1.71 | 60 | 03 | null | 2018-04-30 | ARISTOTLE TRIAL | null | N | SCOPE2 TRIAL | 100515975 |
| 20065801 | 20086911 | 1.74 | 77 | 03 | 2020-06-06 | 2020-06-13 | PLATO Trials | 02 | N | PLATO TRIAL | 101841107 |
| 20065823 | 20086912 | 1.77 | 60 | Palliative (P) | null | 2019-10-28 | MITOMYCIN | null | N | GO2 TRIAL | 100850182 |
| 20065871 | 20086913 | 1.6 | 52.6 | Curative (C) | 2017-05-05 | 2017-05-08 | PACLITAXEL | 02 | N | CAP + RT | 101707420 |
| 20065892 | 20086914 | 1.66 | 48 | Adjuvant (A) | null | 2017-04-13 | CHOP R | 1 | N | GO2 TRIAL | 101497512 |
| 20065951 | 20086915 | 1.88 | 103 | Palliative (P) | 2018-06-14 | 2018-06-20 | EC | 02 | N | CYCLOPHOSPHAMIDE + RITUXIMAB + VINCRISTINE | 101644572 |